The Department of Cardiovascular Medicine at NINGBO MEDICAL CENTER LIHUILI HOSPITAL is a provincial and municipal key discipline, a key medical discipline in Ningbo, a commissioned unit of Ningbo Quality Control Center for Cardiovascular Interventional Diagnosis and Treatment, a training base of the National Health and Health Commission/Chinese Physicians Association/Zhejiang Interventional Diagnosis and Treatment Techniques for Cardiovascular Diseases, National Chest Pain Center, National Heart Failure Center, National Atrial fibrillation center, and a guiding unit of Ningbo Heart Failure Center Alliance.

There are three wards in the Department of Cardiovascular Medicine, with 146 beds and 49 physicians, in which 17 are holders of senior professional titles, 2 are doctoral supervisors, and 5 are master supervisors. With more than 78,000 outpatient visits and 6,500 discharges per year, the department is well-equipped with advanced cardiovascular clinical instruments and equipment and is able to diagnose various kinds of adult cardiovascular diseases, and the level of treatment technology is advanced and has an access to a high reputation in Zhejiang Province.

The Department of Cardiovascular Medicine was the first practitioner to open a cardiac catheterization lab in Ningbo, and took the lead to perform coronary angiography, cardiac electrophysiology diagnosis and treatment and cardiac physiological pacemaker implantation in Ningbo, with the quality levels of operating procedure outrunning similar hospitals of China. It is one of the few units in Ningbo that are able to perform interventional blocking of congenital heart disease. Cardiac catheterization intervention has been developed as a specialty of the department. The Department of Cardiovascular Medicine owns three special cardiac catheterization labs with a gross number of nearly 5,000 interventions operated per year. The department routinely performs interventions for various types of cardiac diseases, including percutaneous interventions for valvular diseases (including aortic, mitral and tricuspid valve lesions), coronary interventions (including treatment of acute myocardial infarction, stable coronary disease and complex lesions of coronary disease), electrophysiological examination of cardiac arrhythmias and radiofrequency ablation (including supraventricular tachycardia, atrial tachycardia, atrial flutter, atrial fibrillation, premature ventricular beats and ventricular tachycardia), pacemaker implantation (including CRT/CRTD/ICD, His bundle pacing, left bundle branch pacing, leadless pacemaker), left auricular occlusion, congenital heart disease intervention (including atrial septal defect occlusion, foramen ovale occlusion, and arteriovenous catheter occlusion), and ECMO for various critical illnesses (e.g.: severe myocarditis).

The Department of Cardiovascular Medicine, in collaboration with the Department of Cardiac Surgery, forms the cardiac innovation team of Ningbo to perform hybridization procedures for various complex heart diseases. The Department of Cardiovascular Medicine, in collaboration with the Department of Cardiac Surgery, optimizes the treatment strategy for heart valve disease; performs internal and external hybridization of complex coronary lesions; perform internal and external treatment of persistent atrial fibrillation, increase the success rate of atrial fibrillation treatment; perform the combined therapy of end-stage heart failure, use the latest cutting-edge technologies such as left ventricular assist devices and heart transplantation, and protect those with end-stage heart failure in the region.